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RESEARCH
Safety and effectiveness of first line eflornithine for
Trypanosoma brucei gambiense sleeping sickness in Sudan:
cohort study
Gerardo Priotto, medical epidemiologist,1 Loretxu Pinoges, statistician,1 Isaac Badi Fursa, registered
medical assistant,2 Barbara Burke, medical doctor,2 Nathalie Nicolay, medical doctor,1 Guillaume Grillet,
medical doctor,2 Cathy Hewison, medical doctor,2 Manica Balasegaram, medical doctor2
ABSTRACT
Objective To assess the safety and effectiveness of
eflornithine as first line treatment for human African
trypanosomiasis.
Design Cohort study.
Setting Control programme in Ibba, southern Sudan.
Participants 1055 adults and children newly diagnosed
with second stage disease in a 16 month period.
Main outcome measures Deaths, severe drug reactions,
and cure at 24 months.
Results 1055 patients received eflornithine for 14 days
(400 mg/kg/day in adults and 600 mg/kg/day in a
subgroup of 96 children). Overall, 2824 drug reactions
(2.7 per patient) occurred during hospital stay, 1219
(43.2%) after the firstweek. Severe reactions affected138
(13.1%) patients (mainly seizures, fever, diarrhoea, and
bacterial infections), leading to 15 deaths. Risk factors for
severe reactions included cerebrospinal fluid leucocyte
counts ≥100×109/l (adults: odds ratio 2.6, 95%
confidence interval1.5 to4.6), seizures (adults:5.9,2.0 to
13.3), and stupor (children: 9.3, 2.5 to 34.2). Children
receiving higher doses did not experience increased
toxicity. Follow-up data were obtained for 924 (87.6%)
patients at any follow-up but for only 533 (50.5%) at
24 months. Of 924 cases followed, 16 (1.7%) died during
treatment, 70 (7.6%) relapsed, 15 (1.6%) died of disease,
403 (43.6%)were confirmedcured, and420 (45.5%)were
probably cured. The probability of event free survival at
24 months was 0.88 (0.86 to 0.91). Most (65.8%, 52/79)
relapses and disease related deaths occurred after
12 months. Risk factors for relapse included being male
(incidence rate ratio 2.42, 1.47 to 3.97) and cerebrospinal
fluid leucocytosis: 20-99×109/l (2.35, 1.36 to 4.06);
≥100×109/l (1.87, 1.07 to 3.27). Higher doses did not
yield better effectiveness among children (0.87 v 0.85,
P=0.981).
Conclusions Eflornithine shows acceptable safety and
effectiveness as first line treatment for human African
trypanosomiasis. Relapses did occur more than
12 months after treatment. Higher doses in children were
well tolerated but showed no advantage in effectiveness.
INTRODUCTION
Human African trypanosomiasis (sleeping sickness),
caused by the protozoan Trypanosoma brucei gambiense
and transmitted by the bite of the tsetse fly, represents
an important threat in several sub-Saharan countries.
In southern Sudan the disease is endemic in all of
western Equatoria, the province bordering Uganda,
Democratic Republic of Congo, and Central African
Republic. In the past the disease has been controlledby
active surveillance and treatment of cases and its
prevalencewas kept at low levels (0.3-0.5%) until 1989.
Control activities disintegrated amid civil war, and
massive population movements favoured the re-
emergence of the disease in epidemic proportions.
Human African trypanosomiasis is invariably fatal
unless treated. The disease progresses from haemo-
lymphatic infection (first stage disease) to meningoen-
cephalitic invasion (second stage). Most patients with
second stage disease are treated with a series of
intravenous injections of melarsoprol. This drug has
beenused since 1949 but is associatedwith severe toxic
effects, in particular a reactive encephalopathy, which
affects 5-10% of patients, with 10-70% of these cases
dying.1 2 The encephalopathy cannot be predicted,
prevented, or managed satisfactorily, despite half a
century of investigations. Melarsoprol related death
rates are about 6%.3 An additional concern is the
increase in treatment failures withmelarsoprol, as high
as 30%, reported in several foci in Uganda, Sudan,
Democratic Republic of Congo, and Angola.4-6 In
southern Sudan, 18.5% of the first group of patients
treated by Médecins Sans Frontières in 1999 with a
10 day course of melarsoprol (2.2 mg/kg/day) had
relapsed after six months of follow-up.
Eflornithine (diethylfluoromethylornithine or
DFMO), initially evaluated for the treatment of cancer,
is the only alternative drug registered for the treatment
of second stage human African trypanosomiasis. The
drug exerts a trypanostatic effect by inhibiting the
parasite’s ornithine decarboxylase, an enzyme needed
for the synthesis of polyamines, themselves involved in
cell multiplication and differentiation.7-9 After
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intravenous administration eflornithine has a short
half-life (1.5-5 hours)10-13 and penetrates the blood-
brain barrier well.
Adverse effects of eflornithine include seizures,
gastrointestinal disorders, and myelosuppression. A
major disadvantage of the drug is the labour intense
mode of its administration, requiring one intravenous
infusion every six hours for 14 days (56 infusions in
total). Before 2001, when a five year donation from the
manufacturer (Sanofi-Aventis) to the World Health
Organizationmade eflornithine available to allAfrican
countries, its extensive use was unaffordable. For these
reasons eflornithine has been used on a small scale,
mostly reserved for second line treatment.
In view of the increasingly high relapse rates with
melarsoprol and its known high toxicity, Médecins
Sans Frontières adopted eflornithine as first line
therapy for human African trypanosomiasis in its
treatment centre based in Ibba, Maridi county, south-
ern Sudan, in September 2001, as soon as the drug
became financially accessible.
This centre was the first to use eflornithine on a large
scale, offering a unique opportunity to document
clinical results.Weassessed the safety andeffectiveness
of first line treatment with eflornithine for second stage
human African trypanosomiasis in a remote endemic
focus.
The area was strongly affected by years of war and
isolation. It lacked infrastructure, safe water, and an
electricity and communications network; had poor
roads, impractical to use for part of the year; insecurity
(constant danger of air and land attacks by military
forces or bandits); and low levels of education; and
lacked trained human resources. The Médecins Sans
Frontières team had gone through emergency evacua-
tions repeatedly. The setting did not meet the
minimum conditions for planning a rigorous clinical
trial, ideally with a randomised controlled design and a
good follow-up, which would have provided sounder
data. In addition, a comparative studywith the existing
alternative treatment (melarsoprol) seemed unsustain-
able ethically because of the known higher death rate
plus the low effectiveness of melarsoprol documented
in this area.
METHODS
Our cohort comprised patients with newly diagnosed
second stage human African trypanosomiasis who
were treated with eflornithine in the Ibba Sleeping
Sickness Centre, Maridi county, southern Sudan
between September 2001 and December 2002.
We defined patients as having second stage disease if
trypanosomes were found in cerebrospinal fluid, if the
numberof leucocytes in cerebrospinal fluidwas greater
than 5×109/l with trypanosomes in blood or lymph, or
if the number of leucocytes in cerebrospinal fluid was
greater than 20×109/l with a card agglutination test for
trypanosomiasis14 dilution titer of 1:4 or higher.
Patients were Sudanese from western Equatoria.
They were diagnosed as having human African
trypanosomiasis by active screening or passively at
the Médecins Sans Frontières laboratories in Ibba,
Maridi, and Kotobi (Maridi and Mundri counties).
Diagnostic examinations included microscopy of
lymph node fluid and blood (with capillary tube
centrifugation15 and quantitative buffy coat16 techni-
ques), cerebrospinal fluid for parasite detection and
leucocyte counts, as well as serology with the card
agglutination test for trypanosomiasis.
Patients testing positive for malaria (rapid test or
microscopy) were treated with a combination of
artesunate and sulfadoxine-pyrimethamine before
starting the eflornithine regimen.
Eflornithine diluted in normal saline was adminis-
tered in slow intravenous infusions over two hours.
Adults received 100 mg/kg every six hours (400 mg/
kg/day) for 14 days. Children received a higher dose—
150 mg/kg every six hours (600 mg/kg/day) for
14 days—on the basis of previous reports17 18 that
showed lower effectiveness among under 12s asso-
ciated with lower concentrations of eflornithine in
cerebrospinal fluid. This higher dose for children was
adopted in January 2002 with an age cut-off point
initially set at 15 years, modified later in 2002 to
Table 1 | Baseline characteristics of 1055 patientswith newly diagnosed second stage human
African trypanosomiasis treatedwith eflornithine in Ibba, southern Sudan. Values are numbers
(percentages) of patients unless stated otherwise
Characteristics Patients with sleeping sickness (n=1055)
Women 468 (44)
Median (interquartile range) age (years) 22 (15-32)
Age <15 years 226 (21)
Median (interquartile range) weight (kg) 46 (38-54)
County of residence:
Mundri 676 (64)
Maridi 276 (26)
Other 103 (10)
Detected by active screening 121 (12)
Malaria coinfection 445 (42)
Axillary temperature ≥37.5°C 357 (34)
Glasgow coma score* (n=1012):
10 7 (1)
11 1 (0.1)
12 2 (0.2)
13 6 (1)
14 22 (2)
15 974 (96)
Localisation of trypanosomes:
Lymph nodes 683 (65)
Blood 330 (31)
Lymph or blood 1005 (95)
Cerebrospinal fluid 351 (33)
Leucocyte count in cerebrospinal fluid:
Geometric mean×109/l 43.9
≤20×109/l 450 (43)
21-99×109/l 256 (24)
≥100×109/l 349 (33)
*Score is sum of points obtained in each of three criteria (best motor response, best verbal response, eye
opening): 3-8=severe impairment; 9-12=moderate impairment; 13-14=mild impairment; and 15=normal.
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12years.Thereforeamongunder15s in thecohortonly
a subgroup received the higher dose.
Wedidnot giveeflornithine topregnantwomen, and
breastfed childrenofmothers receiving treatmentwere
given a breast milk replacement. All patients were
admitted to hospital for round the clock medical
surveillance for the whole period of treatment.
The clinician in charge interrupted or stopped
treatment according to the severity of adverse reac-
tions. Treatments were resumed from the point of
interruption when the patient’s condition improved.
We characterised all adverse events occurring in
temporal association with treatment using the inter-
national common toxicity criteria,19 which grades
adverse events by intensity from1 to4 (mild,moderate,
severe, very severe), the relation between the drug and
event (not related, unlikely, possible, probable, defi-
nite, unknown), and outcome (complete recovery, still
present at discharge, sequelae, death). Drug reactions
did not include adverse events classed in the “not
related” category.
We graded adverse events retrospectively on the
basis of medical records and discussion with patients’
clinicians.
After treatment we followed-up patients at 6, 12, and
24 months with routine clinical and laboratory para-
sitological assessments including blood concentration
techniques and lymph node fluid and cerebrospinal
fluid examinations. Patients whomissed appointments
were interviewed at home about their health status.We
regarded those who were in good general health at
24 months or later but refused to travel for the final
laboratory assessment as “probably cured.”
We considered a relapse to have occurred when
trypanosomes were seen in any body fluid or if the
cerebrospinal fluid leucocyte count had significantly
increased. Patients who relapsed were re-treated for
10 days with a combination of melarsoprol 1.2 mg/kg
and nifurtimox (15 mg/kg/day for adults and 20 mg/
kg/day for under 15s).
To improve the follow-up rate, Médecins Sans
Frontières strengthened its resources for patient tracing
and community health education from July 2002
onwards.
Data sources
Weobtainedbaseline and treatment data frommedical
records and entered these in an EpiData 3.0 (EpiData
Association, Denmark) database. Data were cross
verified against the Epitryps (Epicentre, France)
database, admission to hospital registers, laboratory
cards, and field programme lists and reports. The
Médecins Sans Frontières team regularly entered
follow-up laboratory data in the Epitryps database.
Analysis was done with Stata 9.2.
Safety analysis
We focused the analysis of risk factors on major drug
reactions (grade 3 or 4), given the broad spectrum of
symptomatology with sleeping sickness and its invari-
able lethality without treatment.We also explored risk
factors for reactions at injection sites.
Logistic regression was used for univariable and
multivariable analysis of risk factors. For the multi-
variable analysis we used a backward elimination
process and comparedmodels with the likelihood ratio
test. Further validation was done with automatic
stepwise forward and backward selection methods,
Table 2 | Description of drug reactions during eflornithine treatment in 1055patientswith newly
diagnosed second stage humanAfrican trypanosomiasis. Values are numbers (percentages) of
patients unless stated otherwise
Drug reactions No of reactions*
Median (range)
onset (days)
Onset within
7 days†
Death 15 (1.4) 12 (1-23) 2 (13)
Gastrointestinal:
Diarrhoea (major)‡ 376 (17) (35.6) 7 (0-23) 169 (45)
Nausea, vomiting 162 (15.4) 5 (0-17) 93 (57)
Anorexia 22 (2.1) 8 (0-14) 9 (41)
Neurological:
Tremor 140 (13.3) 5 (1-17) 87 (62)
Dizziness 93 (8.8) 6 (0-14) 54 (58)
Seizures (major) 51 (41) (4.8) 3 (0-15) 36 (71)
Confusion (major) 38 (4) (3.6) 5 (0-14) 22 (58)
Coma (major) 4 (4) (0.4) 8 (2-13) 2 (50)
Ataxia 1 (0.1) 11 0 (0)
Cardiovascular:
Arrhythmia 12 (1.1) 9.5 (3-13) 4 (33)
Oedema (major) 15 (10) (1.4) 6 (2-14) 8 (53)
Shock (major) 1 (1) (0.1) 14 0 (0)
Dermatological:
Reaction at injection site (major) 261 (3) (24.7) 6 (0-19) 138 (53)
Pruritus 67 (6.4) 4 (0-17) 48 (72)
Rash 6 (0.6) 12 (5-19) 1 (17)
Infection:
Tissue infection (major) 37 (6) (3.5) 9 (0-19) 11 (30)
Pneumonia (major) 23 (3) (2.2) 8 (0-29) 10 (44)
Pain:
Abdominal pain 398 (37.7) 5 (0-22) 241 (61)
Headache (major) 329 (1) (31.2) 4 (0-21) 233 (71)
Muscle or joint pain 91 (8.6) 6 (0-17) 52 (57)
Chest pain 48 (4.5) 5 (0-23) 32 (67)
Other:
Fever (major) 325 (67) (30.8) 5 (0-19) 200 (62)
Cough 172 (16.3) 6 (0-16) 99 (58)
Other (major) 137 (10) (13.0) 8 (0-22) 54 (40)
Total No of drug reactions 2824 (2.7)§ 6 (0-29) 1605 (57)
No of patients with major reactions: 138 (13.1)
1 reaction 116 (11) — —
≥2 reactions 22 (2) — —
Total No of major reactions 167 (0.2)§ 6 (0-23)
Interruptions to treatment: 109 (10.3)
Suspended for <24 hours 57 (5.4) — —
Suspended for >24 hours 42 (4.0) — —
Treatment stopped 10 (0.9) — —
*Percentage of entire cohort.
†Percentage of patients with reaction.
‡Grade 3 and 4 of National Cancer Institute common toxicity criteria.
§Incidence of reactions per patient in whole cohort during hospital stay.
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usingmaximum likelihood estimation tests (Wald test).
We tested one degree interaction effects between
variables with plausible biological links.
Effectiveness analysis
Wecarriedout survival analysiswith theKaplan-Meier
method. The follow-up time was calculated from the
date of admission until the date of relapse, death, or last
visit. We used Poisson regression analysis to test risk
factors for relapse.
To permit comparisons with previous publications
andwithmonitoring data from other treatment centres
we also calculated proportions (a more customary
approach). The follow-up timewas calculated from the
date of hospital discharge. Follow-up was considered
complete for patients assessed at 22months or later and
they were not invited for a further visit.
RESULTS
From September 2001 to December 2002, 1771
patients were treated for human African trypanoso-
miasis, of whom 1055 had newly diagnosed second
stage disease and received eflornithine. This group
comprised the study cohort.
Most patients (952, 90.2%) came from Mundri and
Maridi counties and the rest from Yei and Yambio
counties.Adults (medianage22)were thepredominant
group (829, 78.6%). Coinfection with malaria was
detected in 445 (42.2%) patients. Trypanosomes were
seen in lymph or blood in 1005 (95.3%) patients but in
cerebrospinal fluid in only one third. Cerebrospinal
fluid leucocyte counts were greater than 20×109/l in
605 (57.3%) patients (table 1).Nineteenpatients (1.8%)
were diagnosed without direct parasite evidence,
having positive serology at dilutions of 1:4 or higher
combined with more than 20 cells in cerebrospinal
fluid.
Safety
Drug reactions
Overall, 2990 adverse events were recorded during
hospital stay. In most cases the distinction between
events provoked by the treatment, by the disease itself,
or by concomitant conditions could not be clearly
established. Thus the association with eflornithine
treatment was classified as unrelated in 5.5% cases,
unlikely in 9.0%, possible in 36.8%, probable in 35.5%,
definite in 9.2%, and unknown in 4.0%. Excluding the
166 unrelated events, the remaining 2824 were
regarded as drug reactions (table 2).
Most patients (91.2%, 962/1055) experienced drug
reactions, with a mean of 2.7 reactions per patient
(range 0-9; interquartile range 2-4). The overall death
rate was 1.4% (n=15), and 0.4% (1/226) occurred
among the under 15s.
Because the characterisation was done retrospec-
tively, 242 drug reactions could not be graded owing to
insufficient documentation in the medical records. Of
the graded drug reactions, 6.5% (167/2582) were
classified as major (grade 3 or 4), consisting mainly of
67 fever peaks with an axillary temperature of more
than 39.5°C (6% of cohort), 41 seizures (4%), 17
episodes of diarrhoea (2%), and nine bacterial infec-
tions (1%).
Minor (grade 1 or 2) reactions were common (2.5
reactions per patient). Mild and moderate abdominal
pain and headache were predominant, followed by
fever and reactions at injection sites (including
phlebitis). Soft tissue infections and pneumonia were
notably common.
Themedian time toonsetofdrug reactionswasatday
6 of treatment, and 43.2% (1219/2824) of reactions
occurred after day 7. Some of the most predominant
and clinically significant drug reactions were among
those of late onset, such as diarrhoea and bacterial
infections (55% and 65% started after day 7). Most
neurological and dermatological reactions, however,
occurred during the first week. Seizures appeared
consistently at the beginning of treatment (median day
3). Patients recovered well from seizures and only two
intractable cases necessitated stopping treatment.
Drug reactions led to treatment interruptions in 109
(10.3%)patients,butmostwerebrief suspensionsof less
than 24 hours. Treatment was stopped for 10 patients
(<1%).
At the end of hospital stay 88.0% of the drug
reactions had fully subsided. Among all discharged
patients, 19.3%(201/1039)hadat leastonedisordernot
yet fully resolved, the commonest being diarrhoea,
abdominal pain, headache, and cough.Nopatients had
long term sequelae.
Deaths
Overall, there were 15 deaths for which an association
with eflornithinewas possible to varying degrees. In 10
cases the cause of death was unclear; either the doctors
could not distinguish between drug reactions, sleeping
sickness related complications, and coexisting disease,
or the information recorded in the fileswas insufficient.
Eight deaths were attributed to complications of
bacterial infections leading to sepsis, three of them
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Fig 1 | Probability of event free survival among 1055 patients
treated with eflornithine for newly diagnosed second stage
human African trypanosomiasis in Ibba, southern Sudan
RESEARCH
page 4 of 9 BMJ | ONLINE FIRST | bmj.com
 on 8 May 2008 bmj.comDownloaded from 
characterised as a deterioration of pre-existing infec-
tions. Two deaths were associated with severe diar-
rhoea and dehydration, two were sudden deaths of
suspected cardiogenic cause, and three were linked to
complications of unexplained oedema, acute renal
failure, and tuberculosis, respectively. One child (age
2 years)who received eflornithine600mg/kg/daydied
as a result of severe diarrhoea that started on day 11 of
treatment.
Risk factors for drug reactions
In the initial multivariable analysis the risk factors on
admission for major drug reactions, affecting 13.1%
(n=138) of the cohort, included age less than 15 years,
cerebrospinal fluid leucocyte counts of 100×109/l or
higher, confusion, fever, a history of seizures, and
absence of muscle or joint pain. An interaction effect
was, however, observed between age and cerebro-
spinal fluid leucocyte counts, showing a differing
association of cerebrospinal fluid leucocytes with
drug reactions according to age group. Children and
adults were therefore analysed separately and different
risk factors were identified for the groups (table 3).
Among the 226 under 15s, 38 (16.8%) experienced
major drug reactions. Multivariable analysis showed
an increased risk for those presentingwith confusionor
stupor before treatment. All other factors were not
significantlyassociated, includingadoseof 600mg/kg/
day (96 children) compared with 400 mg/kg/day (130
children).
Of the 829 adults, 100 (12.1%) had major drug
reactions. Risk factors among this group after multi-
variable analysis included cerebrospinal fluid leuco-
cyte counts greater than 20×109/l and seizures.
Musculoskeletal pain was a protective factor.
The multivariable exploration of pretreatment risk
factors for reactions at the injection site (261/1055
patients) identified as predictors: age less than 15 years
(odds ratio 1.62, 95% confidence interval 1.16 to 2.26;
P=0.005) and pruritus (odds ratio 1.60, 1.05 to 2.43;
P=0.029).
Effectiveness
Follow-up results
Overall, 533 (50.5% of cohort) patients had a known
outcomeorat least 24monthsof follow-up, 672 (63.7%)
had at least 12 months of follow-up, and 924 (87.6%)
had any follow-up. The cohort was followed-up for a
median 16.5 months (interquartile range 7-26).
Relapses were established in 27 patients without
detection of parasites in body fluids. Among them the
median increase in leucocyte counts since the previous
assessment was 65 cells (range 27-523).
Survival analysis
By survival analysis, the probability of event free
survival for the whole cohort at 24 months was 0.88
(95% confidence interval 0.86 to 0.91; fig 1). At
12 months it was 0.95 (0.93 to 0.96) and at 36 months
it was 0.84 (0.81 to 0.87).
In an alternative survival analysis with no assump-
tions, 29patients seen in apparent goodhealthwerenot
assumed to be “probably cured” but were instead
censored at their last laboratory assessment. Fifteen
patientswhodiedofunverifiedcausesduring follow-up
were not assumed to be “treatment failures” but were
censored at their date of death. Under these conditions
the probability of event free survival at 24 months was
0.90 (0.87 to 0.92).
Among the 226 under 15s the probability of event
Table 3 | Risk factors for developing one ormoremajor drug reactions among1055 patientswith newly diagnosed second stage
humanAfrican trypanosomiasis included in cohort, by age group
Risk factors
Univariable Multivariable
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Children <15 years (n=226)
Trypanosomes in cerebrospinal fluid 2.2 (1.1 to 4.6) 0.028 — NS
Cerebrospinal fluid leucocytes ×109/l:
21-99 v ≤20 0.5 (0.2 to 1.6) 0.269 0.4 (0.1 to 1.4) 0.167
≥100 v ≤20 2.2 (1.0 to 4.7) 0.048 1.6 (0.7 to 3.8) 0.249
Confusion or stupor 8.3 (2.5 to 27.7) 0.001 9.3 (2.5 to 34.2) 0.001
Seizures 5.6 (1.5 to 20.3) 0.009 3.6 (0.9 to 14.6) 0.078
Eflornithine 600 v 400 mg/kg/day 1.1 (0.6 to 2.3) 0.757 — NS
Adults (n=829)
Trypanosomes in lymph or blood 0.3 (0.2 to 0.7) 0.005 0.51 (0.2 to 1.2) 0.107
Trypanosomes in cerebrospinal fluid 2.3 (1.5 to 3.5) <0.001 — NS
Cerebrospinal fluid leucocytes ×109/l:
21-99 v ≤20 2.1 (1.2 to 3.9) 0.013 2.1 (1.2 to 3.9) 0.017
100 v ≤20 3.4 (2.0 to 5.8) <0.001 2.6 (1.5 to 4.6) 0.001
Confusion or stupor 2.9 (1.5 to 5.4) 0.001 1.7 (0.8 to 3.4) 0.151
Seizures 7.3 (3.0 to 17.6) <0.001 5.9 (2.0 to 13.3) 0.001
Musculoskeletal pain 0.5 (0.2 to 0.9) 0.024 0.3 (0.2 to 0.7) 0.003
Dehydration 3.3 (1.0 to 11.0) 0.049 2.6 (0.7 to 9.5) 0.143
NS=Not significant.
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free survival at 24 months per dose group (600 v
400 mg/kg/day) was similar (0.87 v 0.85, log rank
P=0.981). This finding did not change bymultivariable
analysis nor by selecting the131children aged less than
12 years (data not shown).
Customary analysis of proportions
To permit comparisons with other reports and with
programmemonitoring data, the effectiveness data are
also presented in a more customary analysis (table 4).
Of the 924 patients with a known final outcome orwho
were seen at least onceduring follow-up, 16 (1.7%)died
during treatment, 70 (7.6%) relapsed, 15 (1.6%) died of
disease during follow-up, 403 (43.6%) were confirmed
cured, and 420 (45.5%) were probably cured (favour-
able progression until the last assessment). The cure
rate among these patients was 89.1% (n=823). A more
optimistic approach, taking into consideration those
lost to follow-up as cured (12.4%of cohort), gave a cure
rate of 90.4% (n=954).
Time to detection of relapse
Figure 2 shows the time distribution of the detection of
relapses and of deaths due to disease regarded as
compatible with sleeping sickness. The date of death
was not recorded for six patients.Of all 70 relapses plus
the nine deathswith a knowndate regarded as relapses,
27 (34%) were detected within 12 months, 46 (58%)
within 18 months, 63 (80%) within 24 months, and the
remaining 16 (20%) afterwards.
To have a more realistic look at the dynamics of
follow-up, taking into account that numerous patients
attend their visits late, one month was added to each
follow-up time point. As a result 35 (44%) patients
relapsed at 13 months, 52 (66%) at 19 months, and 68
(86%) at 25 months.
Risk factors for relapse
A multivariable Poisson regression analysis (1039
patients discharged) revealed a higher risk of relapse
for men than for women and for patients with high
cerebrospinal fluid leucocytosis (table 5).
DISCUSSION
The use of eflornithine 400 mg/kg/day for 14 days as
routine first line treatment for second stage human
African trypanosomiasis in isolated foci was feasible
and showed satisfactory safety and effectiveness.
Relapses occurred more than 12 months after treat-
ment and therefore long term follow-up of patients is
important. A higher dose in children (600 mg/kg/day
for 14 days) was well tolerated, but it was no more
effective than the standard dose.
Strengths and weaknesses
Previously published clinical data on eflornithine
concerned smaller cohorts with fewer than 300
participants, composed of amix of naive and re-treated
patients anddifferent regimens.This cohort’s strengths
include both its size andhomogeneity: all patientswere
naive cases and received the same treatment regimen.
With only one exception,20 the follow-up of our cohort
wasbetter than inprevious studies.The sample size and
acceptable follow-upprovide amore robustmeasureof
safety and effectiveness.
The safety data were collected retrospectively from
routine medical records. We thought that severe
clinical events were consistently reported but that
inconsequential events tended to be under-reported.
The high turnover of the team (doctors were asked to
commit to six month terms in Ibba) leads to variability
in the quality of reporting over time.
The limited medical equipment and laboratory
capacity did not allow for more conclusive diagnosis
of adverse events and causes of death.
Some caution is needed when interpreting the
findings on effectiveness because of the incomplete
follow-up after treatment, always a challenge in settings
affected by war.
A few patients in the cohort (1.8%, 19/1055) were
diagnosed without directly seeing trypanosomes, on
the basis of serology combined withmore than 20 cells
in the cerebrospinal fluid, which are not universally
accepted criteria.These criteriawereused in this site (as
is the case inother sites) becauseof the low sensitivityof
current laboratory examinations to directly detect the
parasites, coupled with the high level of disease
transmission in the area at the time, plus the high
probability of losing contact with the patients after-
wards.
Table 4 | Outcome after follow-up of 1055patientswith newly diagnosed second stage human
African trypanosomiasis treatedwith eflornithine. Values are percentages unless stated
otherwise
Outcome No of patients
Evaluable group
(n=924)
Whole cohort
(n=1055)
Cured at 24 months 403 43.6 38.2
Probably cured at 24 months* 29 3.1 2.7
Probably cured (partial follow-up)† 391 42.3 37.1
No follow-up 131 — 12.4
Died during treatment 16‡ 1.7 1.5
Relapsed (all in second stage) 70 7.6 6.6
Probably relapsed (died of disease) 15 1.6 1.4
*In good general health but refusing to travel for final laboratory assessment.
†11 patients died of non-disease causes (for example, war) during follow-up.
‡One death was unrelated to treatment.
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Fig 2 | Time to detection of relapses and deaths of disease with known date (n=79). Six patients
with no date of death are excluded
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Safety
Our overall findings on safety are consistent with those
reported in similar settings21 and reaffirm the advan-
tage of eflornithine over melarsoprol. The case fatality
rate of 1.4% is much lower than the fatality rate with
melarsoprol.
Typically, hospital inpatients with second stage
sleeping sickness have numerous adverse events,
regardless of the regimen used. In most cases it cannot
be conclusively established if the adverse events are
provoked by the treatment, by the disease itself, or by
concomitant conditions, and the same dilemma affects
the data from this cohort.
The extraction of data frommedical records showed
that drug reactions with eflornithine were common.
Major drug reactions were, however, relatively
uncommon (13%). The commonest major drug reac-
tions were fever spikes, generalised seizures, and
diarrhoea. In most patients these conditions resolved
favourably with routine management and/or tempor-
ary treatment suspensions.
The frequency of soft tissue infections and pneumo-
nia was higher than anticipated. In the literature we
foundonly onementionof three cases of pyoderma in a
series of 207 patients.22 The late emergence of this
phenomenon reaffirms its probable relation with the
treatment. The fact that this was a first experience of a
large number of patients treated over a sustained
period, in challenging conditions where asepsis is
difficult to ensure, could be a first general explanation.
Infusions were prepared in large numbers, twice a day,
every day. This repetitive routinemay affect the rigour
of the nursing technique. We hypothesised that these
infections might be catheter related and that a
contribution of eflornithine itself is possible, as a
cytostatic drug interfering with the host’s immunity.
After the first cases of serious infection in Ibba, infusion
safety trainingwas reinforcedandapositive impactwas
observed thereafter. We stress that sustained vigilance
needs to be maintained and the best possible safety
materials and techniques must be introduced. Most of
these soft tissue infections were successfully managed
with antibiotics (cloxacillin or cephalosporins).
Theobservation that nearlyhalf of thedrug reactions
emerged after day 7 of treatment is consistent with
results of a previously reported trial,20which compared
eflornithine treatment for 14 days with seven days. It
suggests that considerable drug related toxicity might
be avoided with shorter eflornithine regimens when
suitable. According to our data themain problems that
could hypothetically be averted to some extent are
gastrointestinal and cardiovascular disorders, injection
site reactions, and bacterial infections. Only compara-
tive studies could properly assess this hypothesis.
Risk factors for major drug reactions were estimated
with odds ratios, which are considered good risk
estimators if the phenomenon studied is infrequent,
this being the case for our data. We found that high
leucocyte counts in cerebrospinal fluid increased the
risk of severe drug reactions in adults but not in under
15s. Children but not adults presenting with confusion
or stupor developed more severe reactions. A history
of seizures only in adults was an important risk factor
for severe reactions.
Adults presenting with arthralgia or myalgia had a
lower risk of major toxicity. An explanation might be
that these symptoms are indicative of an earlier stage of
the disease progression.
The Ibba programme was the first to administer a
considerably (50%) higher dose to children, which had
been empirically suggested to improve eflornithine
effectiveness in children but that had not yet been
implemented or described. This cohort included 96
under 15s who received this higher dose. Because we
also had a group of 130 children who for independent
reasons received the standard dose, we examined the
association of the higher dose with major drug
reactions but found no significant increase in toxicity
in children receiving eflornithine 600mg/kg/day.Our
data did not show a difference in effectiveness between
the two doses, which is in contradiction with the
conclusions of previous reports.17 18 20
Effectiveness
Considering the difficult conditions in southern Sudan
and the typical low compliance with follow-up
Table 5 | Risk factors for relapse during follow-up among1039 patientswith newly diagnosed second stage humanAfrican
trypanosomiasis discharged alive after treatmentwith eflornithine
Risk factors
Univariable Multivariable
Incidence rate ratio (95% CI) P value Incidence rate ratio (95% CI) P value
Male 2.58 (1.58 to 4.23) <0.0001 2.42 (1.47 to 3.97) <0.0001
Age <15 years 1.67 (1.06 to 2.62) 0.027 1.52 (0.96 to 2.40) 0.074
Trypanosomes in cerebrospinal fluid 1.57 (1.02 to 2.42) 0.040 — NS
Cerebrospinal fluid leucocytes ×109/l:
21-99 v ≤20 2.37 (1.37 to 4.09) 0.002 2.35 (1.36 to 4.06) 0.002
≥100 v ≤20 2.04 (1.19 to 3.51) 0.010 1.87 (1.07 to 3.27) 0.027
Confusion or stupor 2.18 (1.09 to 4.35) 0.027 1.74 (0.86 to 3.56) 0.126
Oedema 2.41 (0.59 to 9.79) 0.219 3.74 (0.82 to 17.09) 0.088
Skin diseases 0.48 (0.15 to 1.51) 0.209 0.36 (0.10 to 1.26) 0.110
NS=not significant.
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schedules of patients with human African trypanoso-
miasis, the level of follow-up for this cohort was good.
The issue of losses to follow-up in longitudinal
studies of human African trypanosomiasis remains a
dilemma. Patients have a noticeable tendency to miss
follow-up assessments (which always include a lumbar
puncture), especially those in remote, impoverished,
and war stricken regions. Our field observations
indicate that patients who are relapsing tend to come
for assessment because of symptoms; asymptomatic
patients tend to miss assessments owing to lack of
motivation to travel, lack of transportation, subsistence
priorities, displacement (sometimes war related), and
fear of the lumbar puncture; and a small proportion
may have died (resulting from relapses of human
African trypanosomiasis or other causes) without this
information reaching the programme.
Our experience during the effort of active tracing in
this and other cohorts has shown thatmost patients not
attending spontaneously for assessment are in fact
cured or in good health. We believe therefore that the
lost to follow-up group is different to the followed-up
group.Assuming that relapses are less commonamong
the lost to follow-upgroup than among the followed-up
group, excluding them from the analysis leads to
overestimation of failure rates.
Survival analysis is affected by the same dilemma
because patients who are partially or totally lost to
follow-up contribute less to the analysis than thosewho
complete the schedule, among whom are all the
treatment failures.
Most clinicians and researchers in the field consider
two years to be an adequate time to assess “cure” and
hence it is possible to refer to the 0.88 probability of
event free survival at 24 months as the cure rate using
eflornithine in this study. This value is in line with the
89.1% (823/924) cure rate by customary analysis (see
table 4) in which patients who were lost to follow-up
were excluded.
The time to relapse in our cohort underlines the
importance of following patients for more than one
year, since only a third of all relapses and deaths with a
known date were detected within 12 months.
Before its application in Ibba, eflornithine had not
been used on a large scale as first line treatment for
second stage human African trypanosomiasis.
Although the drug has been donated by the manufac-
turer since mid-2001, the application in the field
remains costly because of the need for injection fluids,
catheterisation materials, the logistics of transport and
storage, long hospital stays, and round the clock
nursing care. Since 2007 WHO with funding from
Sanofi-Aventis have provided national programmes
with a kit containing the drug and all materials needed
for treating patients. This initiative alleviates some
aspects of theproblem, but large scale access topatients
in safe conditions remains unmet.
Conclusions
Adverse events were common during treatment with
eflornithine although most were not serious. Major
events were infrequent. Those of clinical concern
included seizures, soft tissue infections, and diarrhoea.
Safety can be improved by the prevention and early
detection of soft tissue infections.
Adults with a history of seizures or high cerebro-
spinal fluid leucocytosis before treatment, as well as
children admitted with confusion or stupor, should be
monitored closely for adverse events during eflor-
nithine treatment.
We believe that treatment programmes for human
African trypanosomiasis should use eflornithine as first
line treatment because the safety and efficacy of this
drug compares favourably to results reported with
melarsoprolunder similar conditions.This ispossible if
the capacity of treatment centres is strengthened in
terms of nursing staff and materials needed for safe
intravenous infusions, as shown in this isolated site.
The occurrence of late relapses emphasises the need
for long term follow-up. The administration of a higher
dose in children was well tolerated but did not show an
advantage in effectiveness.
The complex administration mode of eflornithine
remains a barrier to its implementation, and its
extensive use in monotherapy could bring about the
emergence of parasite resistance. For these reasons,
mid-term and long term alternatives are urgently
needed, such as thedevelopment of drug combinations
and new molecules.
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